Teva wraps up jumbo M&A deal with triple tranche Swissie
Teva completed the final leg of the bond financing for its acquisition of Allergan's generic drugs business on Thursday, issuing a Sfr1bn ($1bn) triple tranche Swiss franc deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: